Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
29
BIB Quote, Financials, Valuation and Earnings
Last price:
$51.50
Seasonality move
:
5.96%
Day range:
$49.49 - $52.41
52-week range:
$47.20 - $69.56
Dividend yield:
0.97%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
7K
Avg. volume:
13.8K
1-year change:
0.71%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingProShares Ultra Nasdaq Biotechnology has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, ProShares Ultra Nasdaq Biotechnology has an estimated downside of -- from its current price of $51.41.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $51.41.
Fair Value
-
According to the consensus of 0 analysts, ProShares Ultra Nasdaq Biotechnology has -- downside to fair value with a price target of -- per share.
BIB vs. S&P 500
-
Over the past 5 trading days, ProShares Ultra Nasdaq Biotechnology has underperformed the S&P 500 by -3.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ProShares Ultra Nasdaq Biotechnology does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ProShares Ultra Nasdaq Biotechnology has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ProShares Ultra Nasdaq Biotechnology reported revenues of --.
Earnings Growth
-
ProShares Ultra Nasdaq Biotechnology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ProShares Ultra Nasdaq Biotechnology reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-23 | 2021-12-23 | 2022-12-23 | 2023-12-23 | ||
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-23 | 2023-12-23 | 2023-12-23 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
BIB
Sector
Market Cap
--
--
Price % of 52-Week High
73.91%
--
Dividend Yield
0.97%
--
Shareholder Yield
--
--
1-Year Price Total Return
0.71%
--
Beta (5-Year)
1.340
--
Dividend yield:
0.97%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$54.00
200-day SMA
Sell
Level
$59.78
Bollinger Bands (100)
Sell
Level
57.86 - 66.12
Chaikin Money Flow
Buy
Level
55.9M
20-day SMA
Sell
Level
$56.78
Relative Strength Index (RSI14)
Sell
Level
32.14
ADX Line
Sell
Level
6.64
Williams %R
Buy
Level
-81.9039
50-day SMA
Sell
Level
$59.76
MACD (12, 26)
Sell
Level
-2.07
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
34.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Stock Forecast FAQ
In the current month, BIB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BIB average analyst price target in the past 3 months is --.
-
Where Will ProShares Ultra Nasdaq Biotechnology Stock Be In 1 Year?
According to analysts, the consensus estimate is that ProShares Ultra Nasdaq Biotechnology share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About ProShares Ultra Nasdaq Biotechnology?
Analysts are divided on their view about ProShares Ultra Nasdaq Biotechnology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ProShares Ultra Nasdaq Biotechnology is a Sell and believe this share price will rise from its current level to --.
-
What Is ProShares Ultra Nasdaq Biotechnology's Price Target?
The price target for ProShares Ultra Nasdaq Biotechnology over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BIB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ProShares Ultra Nasdaq Biotechnology is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BIB?
You can purchase shares of ProShares Ultra Nasdaq Biotechnology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ProShares Ultra Nasdaq Biotechnology shares.
-
What Is The ProShares Ultra Nasdaq Biotechnology Share Price Today?
ProShares Ultra Nasdaq Biotechnology was last trading at $51.50 per share. This represents the most recent stock quote for ProShares Ultra Nasdaq Biotechnology. Yesterday, ProShares Ultra Nasdaq Biotechnology closed at $51.41 per share.
-
How To Buy ProShares Ultra Nasdaq Biotechnology Stock Online?
In order to purchase ProShares Ultra Nasdaq Biotechnology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
